Mucinous carcinoma of the breast, believed to be an indolent tumor, affects older females. Pure mucinous carcinoma with a\>90% mucinous component has a better prognosis than that of mixed mucinous carcinoma. This carcinoma tends to follow an indolent course with infrequent lymphatic or hematogenic dissemination and to have a favorable prognosis \[[@b1-jptm-2017-03-18]-[@b4-jptm-2017-03-18]\]. Invasive micropapillary carcinoma (IMPC) was first reported by Siriaunkgul and Tavassoli \[[@b5-jptm-2017-03-18]\] in 1993 as a rare subtype of breast carcinoma. IMPC is characterized by tumor cells arranged in tubules with a small or obliterated lumen, which extensively penetrate the lymphatic or vascular space, leading to a high frequency of lymph node metastasis \[[@b6-jptm-2017-03-18]-[@b14-jptm-2017-03-18]\]. In a previous study, axillary lymph node metastases were found in all of 27 patients at the initial diagnosis. Twelve of these patients were followed up, and six died at a mean of 22 months after the initial treatment \[[@b12-jptm-2017-03-18]\]. It is important for pathologists to identify micropapillary formations, as they indicate the potential for aggressive tumor behavior and influence the choice of therapy. Thus, the micropapillary and pure mucinous subtypes of invasive carcinoma are opposites in terms of their biological behavior \[[@b15-jptm-2017-03-18]\]. These two patterns sometimes coexist in the same tumor. Tumor cells in mucinous carcinoma can exhibit different patterns, such as cords, trabeculae, cribriform structures, and solid lobules. Previous studies have suggested that the micropapillary pattern in cases of mucinous carcinoma is associated with aggressive tumor behavior \[[@b16-jptm-2017-03-18]-[@b18-jptm-2017-03-18]\]. The pathogenetic association of this mucinous micropapillary carcinoma (MUMPC) with pure mucinous carcinoma is unclear.

The aim of this study was to characterize the clinicopathological parameters of MUMPC and to compare them with those of pure mucinous carcinoma, IMPC, and invasive ductal and micropapillary carcinoma (IDMPC). Moreover, the prognostic significance of micropapillary features in breast carcinoma was determined.

MATERIALS AND METHODS
=====================

We analyzed 64 patients diagnosed with MUMPC, IMPC, IDMPC, or mucinous carcinoma without micropapillary features (MUC). These 64 cases were diagnosed and treated for breast carcinoma at Inje University Sanggye Paik Hospital between 1997 and 2012. Only cases with tumors containing a ≥90% mucinous component were defined as mucinous carcinoma. Morphologically, micropapillae were defined as clusters of tumor cells separated from surrounding stroma by clear spaces and that exhibited reverse polarity, also known as an "inside-out" growth pattern, whereby the apical pole of the cells faces the stroma rather than the luminal surface \[[@b19-jptm-2017-03-18]\]. MUMPC was defined as a tumor in which micropapillary features constituted \>50% of the tumor epithelial components ([Fig. 1](#f1-jptm-2017-03-18){ref-type="fig"}). Patient age, tumor stage by TNM classification \[[@b20-jptm-2017-03-18]\], lymph node metastasis, nuclear grade, mitotic rate, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, Ki-67 proliferating index, molecular subtype, and survival were recorded. The following antibodies were used for immunohistochemistry (IHC): ER (SP1, Dako, Carpinteria, CA, USA), PR (SP2, Dako), HER2 (HercepTest, Dako), Ki-67 (MIB-1, Dako), cytokeratin (CK) 5/6 (D5/16, Dako), and epidermal growth factor receptor (EGFR; E30, Dako). Cases were classified as ER-, PR-, and HER2-positive or negative, and the latest American Society of Clinical Oncology guidelines for the detection and scoring of ER, PR, and HER2 were followed \[[@b21-jptm-2017-03-18],[@b22-jptm-2017-03-18]\]. Cases with a HER2 IHC grade of 2+ subsequently underwent evaluation of *HER2* amplification by fluorescence *in situ* hybridization (PathVysion, Abbott, Des Plaines, IL, USA) and were designated as positive or negative. Ki-67 expression was classified as low (\<14%) or high (≥14%) \[[@b23-jptm-2017-03-18]\]. Based on the IHC results, molecular subtypes were defined as follow: luminal A (ER^+^ and/or PR^+^, HER2^--^, Ki-67 low), luminal B (ER^+^ and/or PR^+^, HER2^+^/ER^+^ and/or PR^+^, HER2^--^, Ki-67 high), HER2-positive (ER^--^, PR^--^, HER2^+^), and basal-like (ER^--^, PR^--^, HER2^--^, EGFR^+^ and/or CK5/6^+^) \[[@b23-jptm-2017-03-18]\]. Patients underwent either mastectomy or breast conserving surgery with lymph node dissection. Adjuvant chemotherapy or hormonal therapy was routinely considered. All patients underwent mammography, physical examination, chest X-ray, and breast ultrasonography during follow-up of 6 to 96 months. This study was approved by the Institutional Review Board of our hospital (SGPAIK 2016-04-002).

The following clinical and pathological factors were assessed: age at diagnosis, nuclear grade (a one-level increase on a 1--3 scale), mitotic rate (a one-level increase on a 1--3 scale), ER expression (positive vs negative), PR expression (positive vs negative), HER2 amplification (positive vs negative) and the Ki-67 proliferation index (high vs low). Molecular tumor subtypes were categorized as luminal A, luminal B, basal-like, or HER2 positive. The clinicopathological features of MUC, MUMPC, IMPC, and IDMPC cases were compared. Pearson's chi-square test, Student's t test, and ANOVA were used to evaluate discrete and quantitative variables. Among the clinicopathological variables, the potential risk factors for overall survival (OS) were examined using univariate and multivariate logistic regression analyses. Statistical analyses were performing using IBM SPSS Statistics ver. 20 software (IBM Corp., Armonk, NY, USA). Statistical significance was determined using the likelihood ratio test and accepted at values of p\<.05.

RESULTS
=======

The 64 cases comprised 19 (29.7%) with MUC, 17 (26.6%) with MUMPC, 15 (23.4%) with IMPC, and 13 (20.3%) with IDMPC. All cases were female and aged 29--79 years (mean, 51.8±12.8 years).

Both MUC and MUMPC showed low nuclear grades and low mitotic rates. In both groups, all tumor cells were positive for ER, irrespective of the presence of micropapillary features. All but one of the MUC cases revealed strong PR expression but no *HER2* amplification. All but one of the MUMPC cases were positive for PR and negative for *HER2* amplification. A high Ki-67 proliferation index was noted in eight cases of MUC (42.1%) and 10 cases of MUMPC (58.8%). Among the MUC and MUMPC cases, 11 (57.9%) and seven cases (41.2%) were luminal A, respectively, and eight (42.1%) and 10 cases (58.8%) were luminal B. Neither the HER2 nor basal-like subtype was detected in MUC or MUMPC. Among the MUC cases, 11 cases (57.5%) were T1, seven cases (36.8%) were T2, and a case (5.3%) was T3. Among the MUMPC, six cases (35.3%) were T1, seven cases (41.2%) were T2, and four cases (23.5%) were T3. Metastasis to the axillary lymph node was detected in two cases of MUC (10.5%) and four cases of MUMPC (23.5%). The surrounding breast parenchyma showed changes suggestive of ductal carcinoma *in situ* in 13 cases (36.1%), comprising eight cases of MUC and five of MUMPC ([Table 1](#t1-jptm-2017-03-18){ref-type="table"}).

Compared with IMPC and IDMPC, nuclear grade and mitotic rate were lower in MUMPC (p\<.01). MUMPC showed lower frequency of ER and PR negativity (p=.04) and HER2 positivity (p=.01). The Ki-67 proliferation index of the MUMPC cases was lower than that of the IMPC and IDMPC cases (p\<.01). Upon comparison of MUC and MUMPC, IMPC and IDMPC revealed less frequent luminal A and more frequent HER2 and basal-like subtypes (p\<.01). Among the MUMPC cases, six cases (35.3%) were T1, seven cases (41.2%) were T2, and four cases (23.5%) were T3. Among the IMPC and IDMPC cases, six cases (40.0%) and four cases (30.8%) were T1, six cases (40.0%) and seven cases (53.8%) were T2, and three cases (20.0%) and two cases (15.4%) were T3, respectively. Four of the MUMPC cases (23.5%) exhibited lymph node involvement, while metastasis to the axillary lymph node was detected in 12 (80.0%) and nine (69.2%) cases of IMPC and IDMPC, respectively (p\<.01) ([Table 1](#t1-jptm-2017-03-18){ref-type="table"}). The surrounding breast parenchyma showed changes suggested of ductal carcinoma in situ in 19 cases (67.9%), comprising eight cases of IMPC and 11 of IDMPC.

Mean follow-up duration was 83±51 months. Overall, PR and HER2 statuses, T-stage, and lymph node metastasis were correlated with death ([Table 2](#t2-jptm-2017-03-18){ref-type="table"}). Univariate analysis using a logistic regression model revealed that OS was significantly associated with PR and HER2 statuses, T-stage, and lymph node metastasis ([Table 3](#t3-jptm-2017-03-18){ref-type="table"}). However, on multivariate analysis, only T-stage was significantly associated with OS ([Table 3](#t3-jptm-2017-03-18){ref-type="table"}).

DISCUSSION
==========

Pure mucinous carcinoma of the breast has a good prognosis with a low rate of regional lymph node metastasis and excellent survival, in contrast to invasive ductal carcinoma of no special type \[[@b2-jptm-2017-03-18]\]. In this study, pure mucinous carcinoma showed a low rate of nodal involvement (16.7%) and a high rate of OS (91.7%). This indolent behavior is associated with a relatively low level of genomic instability, low proliferative activity, positivity for hormone receptors, and low *HER2* amplification \[[@b2-jptm-2017-03-18],[@b24-jptm-2017-03-18],[@b25-jptm-2017-03-18]\]. In the present study, pure mucinous carcinoma showed a low nuclear grade, diffuse and strong expression of hormone receptors, and very low expression of HER2.

A micropapillary architecture in breast carcinoma has been reported to result in a poor prognosis \[[@b17-jptm-2017-03-18],[@b18-jptm-2017-03-18],[@b26-jptm-2017-03-18],[@b27-jptm-2017-03-18]\]. In one study, 86% of mucinous carcinomas had a micropapillary pattern \[[@b28-jptm-2017-03-18]\]. The micropapillary architecture can be ignored in tumors with a large quantity of extracellular mucin as detected by low-power microscopy \[[@b16-jptm-2017-03-18]\]. A micropapillary pattern has been identified in pure mucinous carcinoma, although its prognostic significance is unclear. In this study, 17 of 36 cases of mucinous carcinoma (47.2%) had micropapillary features. As reported in a previous study, these micropapillary subtypes of mucinous carcinoma impact patient survival via their propensity for nodal metastases, depending on the amount of mucin within the tumor \[[@b16-jptm-2017-03-18],[@b28-jptm-2017-03-18]\]. The study also demonstrated that even tumors classified as MUMPC can lead to IMPC-type metastasis. Prior studies have reported that mucinous carcinomas result in nonmucinous or ductal metastasis \[[@b29-jptm-2017-03-18]\]. However, the results are conflicting. In the current study, four of 17 MUMPC cases (23.5%) had lymph node metastases of the ductal, micropapillary, or mucinous type. MUC and MUMPC were not significantly influenced by the presence of micropapillary features. It has been demonstrated in both types that abundant extracellular mucin contributes to the slower spread of pure mucinous carcinoma by functioning as a physical barrier between the neoplastic cells and surrounding stroma \[[@b30-jptm-2017-03-18],[@b31-jptm-2017-03-18]\]. This suggests that abundant mucin is a more important prognostic factor than is the presence of micropapillary features. The micropapillary pattern in mucinous carcinoma indicates a possible histogenetic association with IMPC. Indeed, the ability of IMPC to undergo at least partial mucinous differentiation has been reported \[[@b8-jptm-2017-03-18],[@b9-jptm-2017-03-18],[@b14-jptm-2017-03-18]\].

We separately reviewed 45 cases of breast carcinoma with micropapillary features, of which 17 cases were MUMPC, 15 IMPC, and 13 IDMPC, and found that nuclear grade; mitotic rate; ER, PR, HER2, and Ki-67 expression; and lymph node status differed significantly among the subtypes (p\<.05). MUMPC and IMPC have been reported to have similar high nuclear grades, with 70%--80% having florid mitotic activity \[[@b10-jptm-2017-03-18],[@b11-jptm-2017-03-18],[@b18-jptm-2017-03-18],[@b32-jptm-2017-03-18]-[@b34-jptm-2017-03-18]\]. This suggests that MUMPC and IMPC are components of the same spectrum; they show similar nuclear grades and vary only in their mucin content. In contrast, compared with patients with IMPC, those with MUMPC have a better prognosis irrespective of tumor stage \[[@b16-jptm-2017-03-18]\]. In the present study, MUMPC cases had lower and intermediate nuclear grades and a lower mitotic rate than those of IMPC cases. These results indicate that MUMPC exhibits a level of aggressiveness intermediate to those of pure mucinous carcinoma and IMPC.

Previous studies have reported high HER2 expression and low hormone receptor expression in IMPC of the breast \[[@b6-jptm-2017-03-18],[@b15-jptm-2017-03-18],[@b17-jptm-2017-03-18],[@b27-jptm-2017-03-18],[@b32-jptm-2017-03-18]\]. IMPC has a high propensity for lymph node metastasis and more frequent involvement of the lymph nodes compared with invasive ductal carcinoma \[[@b35-jptm-2017-03-18]\]. In this study, four cases of MUMPC (23.5%) had lymph node metastasis; however, synchronous lymph node metastasis was detected in 12 cases of IMPC (80.0%) and nine cases of IDMPC (69.2%). In IMPC, histologic grade, lymphatic vessel density, and lymphocyte infiltration might influence lymph node metastasis \[[@b9-jptm-2017-03-18],[@b16-jptm-2017-03-18],[@b33-jptm-2017-03-18],[@b35-jptm-2017-03-18],[@b36-jptm-2017-03-18]\]. In the present study, MUMPC tumors showed high rates of hormone receptor expression: ER and PR were expressed in 17 (100%) and 16 (94.1%) of 17 cases, respectively; one case (5.9%) was positive for *HER2* amplification. A high rate of hormone receptor expression and a low rate of HER2 suggested good prognosis. Hsu and Shaw \[[@b37-jptm-2017-03-18]\] reported no *HER2* amplification in mucinous breast cancer, suggesting that *HER2* is rarely involved in its tumorigenesis; low *HER2* amplification might also contribute to a better prognosis of this cancer.

Most cases of IMPC are associated with nodal metastases and a poor prognosis \[[@b12-jptm-2017-03-18],[@b13-jptm-2017-03-18],[@b34-jptm-2017-03-18],[@b38-jptm-2017-03-18],[@b39-jptm-2017-03-18]\]. There were typically multiple metastases, with 51% of cases having three or more positive lymph nodes \[[@b13-jptm-2017-03-18],[@b35-jptm-2017-03-18]\]. The average number of metastatic lymph nodes was shown to be 10.7 \[[@b38-jptm-2017-03-18]\]. In addition, lymphatic and vascular invasion has been reported in 33%--67% of cases \[[@b5-jptm-2017-03-18],[@b8-jptm-2017-03-18],[@b12-jptm-2017-03-18]\]. In this study, 12 of 15 IMPC cases (80.0%) exhibited synchronous axillary lymph node metastasis. Of these 12 cases, multiple lymph node metastases (\>4) were noted in five cases (41.7%). The mechanism underlying the high incidence of lymph node metastasis in IMPC is unclear, and the intrinsic subtype is considered an important prognostic factor \[[@b40-jptm-2017-03-18],[@b41-jptm-2017-03-18]\].

The prognosis of luminal A type breast cancer is markedly superior to that of HER2-positive and triple-negative breast cancers. A previous study reported that MUMPC revealed more prevalent luminal B or HER2 subtypes than MUC \[[@b42-jptm-2017-03-18]\]. However, we could not identify the clinical significance of breast carcinoma molecular subtype since there was no HER2 positivity in either MUC or MUMPC cases in this study.

In conclusion, our findings suggest heterogeneous biological behavior among tumors with a micropapillary architecture. Morphologically, MUMPC shares features with both mucinous carcinoma and IMPC, which could result in its intermediate clinical behavior. Although IMPC and IDMPC are aggressive tumors, the presence of micropapillary features in MUMPC was not associated with poorer prognosis. It can be postulated that MUMPC has a more favorable prognosis than that of IMPC, and that the micropapillary pattern in mucinous carcinoma does not contribute to its aggressive behavior. However, further analyses involving a larger cohort are required to clarify the pathogenetic relationships among these tumor types. Furthermore, the classical tumor stage was the strongest predictor of prognosis.
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![Micropapillary features were found in more than 50% of the mucinous carcinoma cases.](jptm-2017-03-18f1){#f1-jptm-2017-03-18}

###### 

Comparisons of clinicopathological parameters among MUC, MUMPC, IMPC, and IDMPC

  Parameter                       MUC (n = 19)   MUMPC (n = 17)   IMPC (n = 15)   IDMPC (n = 13)   p-value^[a](#tfn1-jptm-2017-03-18){ref-type="table-fn"}^
  ---------------- -------------- -------------- ---------------- --------------- ---------------- ----------------------------------------------------------
  Age, mean (yr)                  52.7 ± 14.0    53.9 ± 11.8      45.9 ± 11.7     54.3 ± 12.6      .22^[b](#tfn2-jptm-2017-03-18){ref-type="table-fn"}^
  NG               Low            6 (31.6)       1 (5.9)          0               0                \< .01
                   Intermediate   11 (57.9)      14 (82.4)        4 (26.7)        4 (30.8)         
                   High           2 (10.5)       2 (11.8)         11 (73.3)       9 (69.2)         
  Mitosis          Low            16 (84.2)      13 (76.5)        2 (13.3)        2 (15.4)         \< .01
                   Intermediate   1 (5.3)        4 (23.5)         3 (20.0)        3 (23.1)         
                   High           2 (10.5)       0                10 (66.7)       8 (61.5)         
  ER               Negative       0              0                5 (33.3)        4 (30.8)         .04
                   Positive       19 (100)       17 (100)         10 (66.7)       9 (69.2)         
  PR               Negative       1 (5.3)        1 (5.9)          7 (46.7)        5 (38.5)         .04
                   Positive       18 (94.7)      16 (94.1)        8 (53.3)        8 (61.5)         
  HER2             Negative       18 (94.7)      16 (94.1)        9 (60.0)        8 (61.5)         .01
                   Positive       1 (5.3)        1 (5.9)          6 (40.0)        5 (38.5)         
  Ki-67            Low            11 (57.9)      7 (41.2)         1 (6.7)         1 (7.7)          \< .01
                   High           8 (42.1)       10 (58.8)        14 (93.3)       12 (92.3)        
  MS               LA             11 (57.9)      6 (35.3)         1 (6.7)         1 (7.7)          \< .01
                   LB             8 (42.1)       11 (64.7)        9 (60.0)        8 (61.5)         
                   HER2           0              0                2 (13.3)        2 (15.4)         
                   Basal-like     0              0                3 (20.0)        2 (15.4)         
  T-stage          1              11 (57.9)      6 (35.3)         6 (40.0)        4 (30.8)         .62
                   2              7 (36.8)       7 (41.2)         6 (40.0)        7 (53.8)         
                   3              1 (5.3)        4 (23.5)         3 (20.0)        2 (15.4)         
  LNM              Absence        17 (89.5)      13 (76.5)        3 (20.0)        4 (30.8)         \< .01
                   Presence       2 (10.5)       4 (23.5)         12 (80.0)       9 (69.2)         

Values are presented as number (%).

MUC, mucinous carcinoma without micropapillary feature; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.

Chi-square test;

ANOVA test.

###### 

Clinicopathological parameters related to death

  Parameter                       Alive         Dead          p-value^[a](#tfn3-jptm-2017-03-18){ref-type="table-fn"}^
  ---------------- -------------- ------------- ------------- ----------------------------------------------------------
  Age, mean (yr)                  51.6 ± 12.3   53.0 ± 16.0   .75^[b](#tfn4-jptm-2017-03-18){ref-type="table-fn"}^
  Category         MUC            19 (100)      0             .20
                   MUMPC          14 (82.4)     3 (17.6)      
                   IMPC           12 (80.0)     3 (20.0)      
                   IDMPC          10 (76.9)     3 (23.1)      
  MUC vs MUMPC     MUC            19 (100)      0             .06
                   MUMPC          14 (82.4)     3 (17.6)      
  NG               Low            7 (100)       0             .34
                   Intermediate   29 (87.9)     4 (12.1)      
                   High           19 (79.2)     5 (20.8)      
  Mitosis          Low            31 (93.9)     2 (6.1)       .14
                   Intermediate   8 (72.7)      3 (27.3)      
                   High           16 (80.0)     4 (20.0)      
  ER               Negative       6 (66.7)      3 (33.3)      .07
                   Positive       49 (89.1)     6 (10.9)      
  PR               Negative       9 (64.3)      5 (35.7)      .01
                   Positive       46 (92.0)     4 (8.0)       
  HER2             Negative       47 (92.2)     4 (7.8)       .01
                   Positive       8 (61.5)      5 (38.5)      
  Ki-67            Low            19 (95.0)     1 (5.0)       .16
                   High           36 (81.8)     8 (18.2)      
  MS               LA             20 (82.9)     0             .05
                   LB             29 (82.9)     6 (17.1)      
                   HER2           2 (50.0)      2 (50.0)      
                   Basal-like     4 (80.0)      1 (20.0)      
  T-stage          1              27 (100)      0             \< .01
                   2              24 (88.9)     3 (11.1)      
                   3              4 (40.0)      6 (60.0)      
  LNM              Absence        36 (97.3)     1 (2.7)       \< .01
                   Presence       19 (70.4)     8 (29.6)      

MUC, mucinous carcinoma without micropapillary feature; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.

Chi-square test;

t test (2-tailed).

###### 

Univariate and multivariate analyses of the associations between clinicopathological parameters and overall survival using logistic regression model

                                Univariate        p-value     Multivariate     p-value
  ---------- ------------------ ----------------- ----------- ---------------- ---------
  Category   MUMPC              1.0               Reference   \-               \-
             IMPC vs MUMPC      1.2 (0.2--6.9)    .87         \-               \-
             IDMPC vs MUMPC     1.4 (0.2--8.4)    .71         \-               \-
  NG                            2.5 (0.7--8.7)    .15         \-               \-
  Mitosis                       1.9 (0.8--4.1)    .13         \-               \-
  ER                            0.3 (0.1--1.2)    .09         \-               \-
  PR                            0.2 (0.1--0.7)    .02         0.7 (0.1--6.6)   .78
  HER2                          7.3 (1.6--33.0)   .01         1.1 (0.1--11)    .92
  Ki-67                         4.2 (0.5--36.0)   .19         \-               \-
  MS         LA                 1.0               Reference   \-               \-
             LB vs LA           0.0               .10         \-               \-
             HER2 vs LA         4.8 (0.6--41.0)   .15         \-               \-
             Basal-like vs LA   1.2 (0.1--13.0)   .88         \-               \-
  T-stage                       15 (3.2--72.0)    .001        14 (2.1--88)     .006
  LNM                           15 (1.8--130.0)   .01         9 (0.6--149)     .11

RR, relative risk; 95% CI, 95% confidence interval; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.
